<--Back to project organisation page
Work package 5
Description of work
Protein kinases represent a significant therapeutic target in many pathologies
as they represent the effectors of cell signaling pathways that control a
variety of cell functions, from cell proliferation, to differentiated cell
function and cell death.
The role of work package 5 in the Prokinase Research project is to test novel
compounds, of both natural and synthetic origin, in various model systems for
their therapeutic potential against a range of diseases. The latter include
cancer (with leukaemia as a specific disease targeted), epilepsy, heart disease
and post-stroke neurodegeneration, leishmaniasis and inflammatory disease.
The protein kinases that have been the focus of the project include tyrosine
kinases (Erb family), Protein kinase C, MAP kinases and Cyclin Dependent
Kinases.
| Groups in WP 5: |
||
| University of
Debrecen Faculty of Medicine, Medical and Health Science Center, Department of Biophysics and Cell Biology |
||
| Prof. János Szöllõsi Prof. György Vereb |
||
| INMED/INSERM Institute of Neurobiology of the Mediterranean Sea |
||
| Dr. Yehezkel Ben-Ari Dr. Anton Ivanov |
||
| University of
Bergen Apoptosis Signaling Group (APSIB) |
||
| Prof. Stein-Ove Døskeland |
||
| University of
Birmingham MRC Centre for Immune Regulation |
||
| Dr. Janet M. Lord |
||
| Ludwig Maximilians
University Munich Department of Pharmacy, Center of Drug Research |
||
| Prof. Angelika Vollmar Dr. Stefan Zahler |
||
| University of Vienna Department of Pharmacognosy |
||
| Prof. Verena M.
Dirsch, Ph.D Vienna, Austria |
||
| The Hebrew
University of Jerusalem - Hadassah Medical School Department of Parasitology |
||
| Prof. Charles L. Jaffe |
||
| Neurokin S.A.R.L | ||
| Dr. Serge Timsit Dr. Benedicte Menn |
||